Date: 2011-11-01
Type of information: R&D agreement
Compound: VaxiRNA® technology
Company: GSK (UK) Alnylam Pharmaceuticals (USA - MA)
Therapeutic area: Infectious diseases
Type agreement: R&D
manufacturing
production
Action mechanism:
Disease:
Details: Alnylam Pharmaceuticals and GSK have formed a collaboration focused on Alnylam's VaxiRNA® technology for certain GSK vaccine products, including influenza. This technology is used to increase virus titers in the production of vaccine products. The GSK collaboration is focused initially on influenza vaccine production in cell culture systems. GSK is the first company to form a collaboration accessing this new platform.
Financial terms: Under the terms of the agreement, GSK will provide funding and certain milestone payments to Alnylam. If successfully applied in the manufacture of commercial product, Alnylam will receive payments on unit product sales. In addition, GSK has obtained an option for VaxiRNA applications toward two additional vaccine products.
Latest news:
